期刊文献+

Biomimetic albumin-modified gold nanorods for photothermo-chemotherapy and macrophage polarization modulation 被引量:9

Biomimetic albumin-modified gold nanorods for photothermo-chemotherapy and macrophage polarization modulation
原文传递
导出
摘要 Nanotechnology-based photothermal therapy has attracted great attention in the past decade. Nevertheless, photothermal therapy has some inherent drawbacks, such as the uneven heat production and limited laser penetration, often leading to insufficient treatment outcomes. Here, we developed a combination strategy to improve cancer therapy. The biomimetic albumin-modified gold nanorods(AuNRs) were prepared with incorporation of paclitaxel(PTX). This therapeutic system was characterized by several features. First, the albumin modification enhanced the biocompatibility and colloidal stability. Second, the surface-coated albumin promoted cellular uptake via the albumin-binding protein pathway. Third, PTX was incorporated via hydrophobic interaction between PTX and the albumin lipophilic domain. Fourth, the system can be used for combined photothermo-chemotherapy for yielding synergistic effects. The antitumor activity of the system was evaluated both in vitro and in vivo using the HCT116 colon cancer cell and tumor model. The combination therapy was found with an enhanced treatment efficiency and no obvious side effect. Most importantly, the thermal effect was also discovered with the ability to modulate the tumor microenvironments and suppress the macrophages polarization towards the M2 pro-tumor phenotype. It could be a mechanism for photothermal immunotherapy. The combination strategy and the system provide a potential method for cancer therapy. Nanotechnology-based photothermal therapy has attracted great attention in the past decade. Nevertheless, photothermal therapy has some inherent drawbacks, such as the uneven heat production and limited laser penetration, often leading to insufficient treatment outcomes. Here, we developed a combination strategy to improve cancer therapy. The biomimetic albumin-modified gold nanorods(AuNRs) were prepared with incorporation of paclitaxel(PTX). This therapeutic system was characterized by several features. First, the albumin modification enhanced the biocompatibility and colloidal stability. Second, the surface-coated albumin promoted cellular uptake via the albumin-binding protein pathway. Third, PTX was incorporated via hydrophobic interaction between PTX and the albumin lipophilic domain. Fourth, the system can be used for combined photothermo-chemotherapy for yielding synergistic effects. The antitumor activity of the system was evaluated both in vitro and in vivo using the HCT116 colon cancer cell and tumor model. The combination therapy was found with an enhanced treatment efficiency and no obvious side effect. Most importantly, the thermal effect was also discovered with the ability to modulate the tumor microenvironments and suppress the macrophages polarization towards the M2 pro-tumor phenotype. It could be a mechanism for photothermal immunotherapy. The combination strategy and the system provide a potential method for cancer therapy.
出处 《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2018年第1期74-84,共11页 药学学报(英文版)
基金 the National Basic Research Program of China (973 Program 2014CB931900 and 2013CB932503) NSFC, China (81373357, 81422048, 81673382 and 81521005) for the support National Center for Protein Science Shanghai, CAS, for the technical support at Electron Microscopy Facility
关键词 Photothermal therapy PACLITAXEL Combination therapy Gold nanorods ALBUMIN Tumor-associated macrophage Photothermal therapy Paclitaxel Combination therapy Gold nanorods Albumin Tumor-associated macrophage
  • 相关文献

参考文献1

二级参考文献28

  • 1Gazelle G. S., Goldberg S. N., Solbiati L., Livraghi T., Radiology,2000,217,633.
  • 2Sathomsumetee S., Rich J. N., Anticancer Drugs, 2006, 17, 1003.
  • 3Horsman M. R., Overgaard J., Clin. Oncol. R. Coll. Radiol., 2007, 19 418.
  • 4Stauffer E R., Int. ,Z Hyperthermia, 2005, 21, 731.
  • 5Eichler K., Mack M. G., Straub R., Engelmann K., Zangos S., Woi- taschek D., Vogl T. J., Radiologe, 2001, 41,915.
  • 6Issels R. D., Abdel-Rahman S., Wendtner C., Falk M. H., Kurze V., Saner H., Aydemir U., Hiddemann W., Eur J. Cancer, 2013, 7, 1599.
  • 7van der Zee J., Gonzalez D., van Rhoon G. C., van Dijk J. D.+ van Putten W. L., Hart A. A., Lancet, 2000, 355, 1119.
  • 8Wust P., Hildebrandt B., Sreenivasa G., Rau B., Gellermann J., Riess H., Felix R., Schlag E M., Lancet Oneol., 2002, 3, 487.
  • 9FeariM., Nat. Rev Cancer, 200g, 5,161.
  • 10Hireh L. R., Stafford R. J., Bankson J. A., Sershen S. R., Rivera B., Price R. E., Hazlc J. D., Halas N. J., West J. L., Proc. Natl. Acad. Sci. USA, 2003, 100, 13549.

同被引文献32

引证文献9

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部